Program Status
Active, not recruitingPhase
Phase 1Prior Immunotherapy Allowed
YesCRC-directed Trial
NoDrugs
BMS-986288, Nivolumab, OpdivoTags
MSI-H/ MMRd, MSS/ MMRpComments
Immunotherapy combination: BMS-986288 plus nivolumab (anti PD-1, Opdivo).
BMS-986288 (anti-CTLA-4 probody) is a probody composed of a modified version of ipilimumab (Yervoy), a recombinant human monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (anti CTLA-4)
At least one previous line of standard therapy received in the metastatic setting.
Measurable disease. At least one lesion that is biopsiable.
| Location | Location Status |
|---|---|
| United States | |
|
Local Institution - 0075 Costa Mesa, California 92627 |
Active, not recruiting |
|
Local Institution - 0050 Orange, California 92868-3201 |
Active, not recruiting |
|
Local Institution - 0005 Aurora, Colorado 80045 |
Active, not recruiting |
|
Local Institution - 0002 Baltimore, Maryland 21287 |
Active, not recruiting |
|
Local Institution - 0004 Saint Louis, Missouri 63110 |
Active, not recruiting |
|
Local Institution - 0001 Hackensack, New Jersey 07601 |
Active, not recruiting |
| Argentina | |
|
Local Institution - 0011 Ciudad Autónoma De Buenos Aires, Buenos Aires 1426 |
Active, not recruiting |
|
Local Institution - 0074 Buenos Aires, Ciudad Autónoma De Buenos Aires C1096AAS |
Active, not recruiting |
|
Local Institution - 0014 Córdoba, Cordoba X5000HXL |
Active, not recruiting |
|
Local Institution - 0013 Río Cuarto, Cordoba 5800 |
Active, not recruiting |
|
Local Institution - 0008 ABB, Distrito Federal C1199 |
Active, not recruiting |
|
Local Institution - 0012 Caba, Distrito Federal C1430 |
Active, not recruiting |
|
Local Institution - 0017 Buenos Aires 1431 |
Active, not recruiting |
|
Local Institution - 0016 Buenos Aires C1280AEB |
Active, not recruiting |
| Canada | |
|
Local Institution - 0006 Toronto, Ontario M5G 2M9 |
Active, not recruiting |
|
Local Institution - 0046 Montreal, Quebec H3T 1E2 |
Active, not recruiting |
|
Local Institution - 0042 Montréal, Quebec H2X 0A9 |
Active, not recruiting |
| Chile | |
|
Local Institution - 0019 Santiago, Metropolitana 7510032 |
Active, not recruiting |
|
Local Institution - 0035 Santiago, Metropolitana 7620002 |
Active, not recruiting |
|
Local Institution - 0009 Santiago, Metropolitana 8420383 |
Active, not recruiting |
|
Local Institution - 0036 Santiago, Región Metropolitana De Santiago 7500921 |
Active, not recruiting |
|
Local Institution - 0010 Viña del Mar, Valparaiso 2520598 |
Active, not recruiting |
| France | |
|
Local Institution - 0034 Bordeaux, Gironde 33075 |
Active, not recruiting |
|
Local Institution - 0022 Saint-Herblain, Loire-Atlantique 44800 |
Active, not recruiting |
|
Local Institution - 0018 Bron Cedex 69677 |
Active, not recruiting |
|
Local Institution - 0026 Marseille 13915 |
Active, not recruiting |
|
Local Institution - 0015 Paris 75248 |
Active, not recruiting |
|
Centre Hospitalier intercommunal de Toulon La Seyne sur Mer Toulon 83100 |
Active, not recruiting |
| Italy | |
|
Local Institution - 0040 Milan, Lombardia 20133 |
Active, not recruiting |
|
Local Institution - 0038 Padova, Veneto 35128 |
Active, not recruiting |
|
Local Institution - 0028 Ancona 60126 |
Active, not recruiting |
|
Local Institution - 0033 Catanzaro 88100 |
Active, not recruiting |
|
Local Institution - 0031 Milan 20162 |
Active, not recruiting |
|
Local Institution - 0039 Roma 00168 |
Active, not recruiting |
| Spain | |
|
Local Institution - 0056 Barcelona, Barcelona [Barcelona] 08035 |
Active, not recruiting |
|
Local Institution - 0054 Barcelona, Catalunya [Cataluña] 08036 |
Active, not recruiting |
|
Local Institution - 0023 Madrid 28041 |
Active, not recruiting |
|
Local Institution - 0024 Majadahonda 28222 |
Active, not recruiting |
|
Local Institution - 0055 Sevilla 41013 |
Active, not recruiting |
|
Local Institution - 0025 València 46026 |
Active, not recruiting |
Inclusion Criteria
Inclusion Criteria:
* Histologic or cytologic confirmation of select solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease and have at least 1 lesion accessible for biopsy
* Eastern Cooperative Oncology Group Performance Status of 0 or 1
* Received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to select solid tumor histologies
Exclusion Criteria
Exclusion Criteria:
* Active, known or suspected autoimmune disease
* Active malignancy requiring concurrent intervention
* Primary Central Nervous System (CNS) malignancies or tumors with CNS metastasis as the only site of disease, will be excluded
Other protocol-defined inclusion/exclusion criteria apply
